.Pharmacolibrary.Drugs.R_RespiratorySystem.R05C_ExpectorantsExclCombinationsWithCoughSuppressant.R05CB13_DornaseAlfaDesoxyribonuc.DornaseAlfaDesoxyribonuc .Pharmacolibrary.Drugs.R_RespiratorySystem.R05C_ExpectorantsExclCombinationsWithCoughSuppressant.R05CB13_DornaseAlfaDesoxyribonuc.DornaseAlfaDesoxyribonuc| name: | DornaseAlfaDesoxyribonuclease | |
| ATC code: | R05CB13 | route: | inhalation |
| compartments: | 1 | |
| dosage: | 2.5 | mg |
| volume of distribution: | 0.1 | L |
| clearance: | 2.4 | L/h/kg |
| other parameters in model implementation | ||
Dornase alfa is a recombinant form of human deoxyribonuclease I (rhDNase) used to break down extracellular DNA in the sputum of cystic fibrosis patients, thereby reducing sputum viscosity and improving pulmonary function. It is approved as a mucolytic therapy primarily in cystic fibrosis and remains in current clinical use.
PK parameters described for cystic fibrosis patients, both adult and pediatric, following standard inhalation administration.